Relmada Therapeutics appoints Cedric O'Gorman MD as Chief Medical Officer

RELMADA THERAPEUTICS, INC.

Dr. O'Gorman appointed CMO effective January 9, 2023, leading medical, clinical, and regulatory for REL-1017 MDD program.
He brings over 20 years CNS experience; previously CMO at Alpha Cognition and SVP at Axsome Therapeutics.
CEO cites his expertise with similar-mechanism antidepressants and key regulatory discussions ahead.
Corporate presentation updated and filed as Exhibit 99.2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.